Pharmacyclics Completes $52.4 Million Registered Direct Offering

Firm News

Olshan’s client Pharmacyclics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company, announced that it completed a $52.4 million registered direct offering of its common stock. Olshan represented Pharmacyclics in this matter.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.